When prostate cancer spreads and stops responding to hormone therapy, treatment options become very limited. A new analysis looked at a two-drug radiation therapy that targets cancer cells directly. The treatment combines two radioactive drugs, actinium-225 and lutetium-177, both attached to a molecule that seeks out prostate cancer cells.
Researchers pooled data from 323 men with this advanced, metastatic, castration-resistant prostate cancer. They found that 78% of men saw some drop in their PSA level—a key blood marker for prostate cancer activity. For nearly half (47%), that drop was substantial—more than 50%. The median overall survival for the group was estimated at 11.8 months. On the safety side, severe toxicities were not common. The most frequent serious side effects were anemia (low red blood cells) in 10% of patients and thrombocytopenia (low platelets) in 6%. Notably, no severe dry mouth was reported, which is a common problem with some other radiation treatments.
It's important to understand what this analysis does and doesn't tell us. The results are encouraging and suggest this combination has activity with a manageable safety profile. However, the evidence comes from a meta-analysis of retrospective studies—meaning researchers looked back at data that was already collected, not from a planned clinical trial. The data is also limited. Because of this, the findings need to be evaluated in prospective trials, which follow patients forward in time, to truly determine long-term efficacy and survival outcomes.
